Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.
A randomized double-blind study was performed to examine the effect of clofibrate on glucose tolerance in subjects with non-insulin-dependent diabetes mellitus (NIDDM). Clofibrate (1.5 g/day) or placebo was administered to 70 patients and an oral glucose tolerance test (OGTT) was performed before and 12 wk after treatment. Blood glucose levels were significantly improved in clofibrate-treated groups at all time points during OGTT, whereas there was no change in insulin levels. Improvement of fasting glucose levels required 8 wk of clofibrate treatment. Insulin binding to erythrocytes demonstrated no significant change in the clofibrate-treated subjects. These results suggest that clofibrate improves glucose tolerance in NIDDM subjects without a change in insulin receptors and that clofibrate increases insulin sensitivity through an unknown postreceptor mechanism.
D001786:Blood Glucose / Q000378:metabolism*; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D004311:Double-Blind Method; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D011897:Random Allocation; D011972:Receptor, Insulin / Q000187:drug effects / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D014280:Triglycerides; D011972:Receptor, Insulin; D002994:Clofibrate